SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Schnabel Dirk)
 

Sökning: WFRF:(Schnabel Dirk) > (2019) > FGF23 and its role ...

FGF23 and its role in X-linked hypophosphatemia-related morbidity

Beck-Nielsen, Signe Sparre (författare)
Centre for Rare Diseases, Aarhus University Hospital, Aarhus, Denmark
Mughal, Zulf (författare)
Royal Manchester Children's Hospital, Manchester, UK
Haffner, Dieter (författare)
Hannover Medical School, Hannover, Germany
visa fler...
Nilsson, Ola, 1970- (författare)
Örebro universitet,Institutionen för medicinska vetenskaper,Karolinska Institutet, Stockholm, Sweden
Levtchenko, Elena (författare)
Katholieke Universiteit Leuven, Leuven, Belgium
Ariceta, Gema (författare)
Hospital Universitario Materno-Infantil Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
de Lucas Collantes, Carmen (författare)
Hospital Niño Jesús, Madrid, Spain
Schnabel, Dirk (författare)
University Children's Hospital of Berlin, Berlin, Germany
Jandhyala, Ravi (författare)
Medialis Ltd, Banbury, UK
Mäkitie, Outi (författare)
Karolinska Institutet
visa färre...
 (creator_code:org_t)
2019-02-26
2019
Engelska.
Ingår i: Orphanet Journal of Rare Diseases. - : BioMed Central (BMC). - 1750-1172. ; 14:1
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND: X-linked hypophosphatemia (XLH) is an inherited disease of phosphate metabolism in which inactivating mutations of the Phosphate Regulating Endopeptidase Homolog, X-Linked (PHEX) gene lead to local and systemic effects including impaired growth, rickets, osteomalacia, bone abnormalities, bone pain, spontaneous dental abscesses, hearing difficulties, enthesopathy, osteoarthritis, and muscular dysfunction. Patients with XLH present with elevated levels of fibroblast growth factor 23 (FGF23), which is thought to mediate many of the aforementioned manifestations of the disease. Elevated FGF23 has also been observed in many other diseases of hypophosphatemia, and a range of animal models have been developed to study these diseases, yet the role of FGF23 in the pathophysiology of XLH is incompletely understood.METHODS: The role of FGF23 in the pathophysiology of XLH is here reviewed by describing what is known about phenotypes associated with various PHEX mutations, animal models of XLH, and non-nutritional diseases of hypophosphatemia, and by presenting molecular pathways that have been proposed to contribute to manifestations of XLH.RESULTS: The pathophysiology of XLH is complex, involving a range of molecular pathways that variously contribute to different manifestations of the disease. Hypophosphatemia due to elevated FGF23 is the most obvious contributor, however localised fluctuations in tissue non-specific alkaline phosphatase (TNAP), pyrophosphate, calcitriol and direct effects of FGF23 have been observed to be associated with certain manifestations.CONCLUSIONS: By describing what is known about these pathways, this review highlights key areas for future research that would contribute to the understanding and clinical treatment of non-nutritional diseases of hypophosphatemia, particularly XLH.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)

Nyckelord

X-linked hypophosphatemia (XLH)
bone dysplasia
dental abscess
ectopic calcification
fibroblast growth factor 23 (FGF23)
hearing impairment
hypophosphatemia
muscle weakness
osteomalacia
phosphate regulating endopeptidase homolog
X-linked (PHEX)
rickets
vitamin D deficiency

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy